{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:52:16Z","timestamp":1792108336599,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Contracept Reprod Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The interlink between bleeding control and contraceptive development has always been an important factor. But after many years of advances in contraceptive technology, this interplay has resulted in development of safer and better contraceptive methods that often offer significantly less bleeding for women with both normal bleeding patterns as well as in those suffering from heavy menstrual bleeding (HMB). Recognition of the success of progestin-only methods, such as the hormonal IUDs, progestin dominant oral contraceptives, and the high dose progestin-only pill in substantially decreasing and controlling menstrual bleeding has led the way. This recognition also led to the development of many [non-contraceptive] protocols to stop acute heavy bleeding as well as manage long-term bleeding [using contraceptive methods as well; as non-contraceptive methods].<\/jats:p><jats:p>But even better, there is a new PLUS. The distinct benefit and risk profiles of the many different progestins now available are intentionally being used either in combination contraceptive pills [COCPs] or alone, to add additional benefits, to decrease side effects and risks, and increase effectiveness and bleeding control.<\/jats:p>","DOI":"10.1186\/s40834-023-00249-5","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T10:14:02Z","timestamp":1696846442000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The progestin revolution 2: progestins are now a dominant player in the tight interlink between contraceptive protection and bleeding control\u2014plus more"],"prefix":"10.1186","volume":"8","author":[{"given":"Donna","family":"Shoupe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,9]]},"reference":[{"key":"249_CR1","unstructured":"Junod SW. FDA\u2019s Approval of the First Oral Contraceptive, Enovid. \"Making History\" column of the July\u2013August 1998 issue of Update, the bimonthly publication of the Food and Drug Law Institute. FDA\u2019s Approval of the First Oral Contraceptive, Enovid | FDA. www.fda.gov\/media\/110456\/download."},{"key":"249_CR2","unstructured":"Contracept Technol Update FDA advisory panel recommends approval for Depo-Provera. 1992;13(10):159\u201360."},{"key":"249_CR3","unstructured":"Turley, Melissa D. The History of Depo Provera. November 29, 2005. https:\/\/www.studymode.com\/essays\/History-Of-Depo-Provera-72396.html."},{"issue":"6","key":"249_CR4","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1007\/s00404-019-05340-4","volume":"300","author":"S Palacios","year":"2019","unstructured":"Palacios S, Colli E, Regidor PA. A multicenter, double-blind, randomized trial on the bleeding profile drospirenone-only pill compared with desogestrel. Arch Gynecol Obstet. 2019;300(6):1805\u201312.","journal-title":"Arch Gynecol Obstet"},{"key":"249_CR5","doi-asserted-by":"crossref","unstructured":"Maybin JA, Maybin, and Critchley, HOD. Menstrual physiology: Implications for endometrial pathology and beyond.\u00a0Hum Reprod Update. 2015;21(6):748\u201361.","DOI":"10.1093\/humupd\/dmv038"},{"issue":"1","key":"249_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/epirev\/mxt009","volume":"36","author":"J Hong","year":"2014","unstructured":"Hong J, Jones M, Gita M. The prevalence and risk factors of dysmenorrhea. Epipidemiol Rev. 2014;36(1):104\u201313.","journal-title":"Epipidemiol Rev"},{"issue":"4","key":"249_CR7","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1097\/01.AOG.0000238343.62063.22","volume":"108","author":"MG Munro","year":"2006","unstructured":"Munro MG, Mainor N, Basu R, Brisinger M, Barreda L. Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: a randomized controlled trial. Obstet Gynecol. 2006;108(4):924\u20139.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"249_CR8","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/j.1479-828X.1997.tb02260.x","volume":"37","author":"F Aksu","year":"1997","unstructured":"Aksu F, Madazli R, Budak E, Cepni I, Benian A. High-dose medroxyprogesterone acetate for the treatment of dysfunctional uterine bleeding in 24 adolescents. Aust N Z J Obstet Gynaecol. 1997;37(2):228\u201331.","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"4","key":"249_CR9","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1097\/01.AOG.0000428646.67925.9a","volume":"121","author":"ACOG committee opinion no","year":"2013","unstructured":"ACOG committee opinion no. 557: Management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. Obstet Gynecol. 2013;121(4):891\u20136 (https:\/\/www.acog.org\/en\/Clinical\/Clinical%20Guidance\/Committee%20Opinion).","journal-title":"Obstet Gynecol"},{"key":"249_CR10","unstructured":"ACOG Committee Opinion Number 785 2019. Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding. https:\/\/www.acog.org\/clinical\/clinical-guidance\/committee-opinion\/articles\/2019\/09\/screening-and-management-of-bleeding-disorders-in-adolescents-with-heavy-menstrual-bleeding."},{"issue":"2","key":"249_CR11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ejogrb.2011.04.025","volume":"158","author":"AH James","year":"2011","unstructured":"James AH, Koides PA, Andul-Kadir R, et al. Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. J Obstet Gynecol Reprod Biol. 2011;158(2):124\u201334.","journal-title":"J Obstet Gynecol Reprod Biol"},{"key":"249_CR12","unstructured":"\u201cMedroxyprogesterone Acetate - Drug Usage Statistics\u201d. ClinCalc. Retrieved 11 April2020. Drug Usage Statistics, United States, 2008\u20132018. https:\/\/clincalc.com\/DrugStats\/Drugs\/MedroxyprogesteroneAcetate."},{"key":"249_CR13","unstructured":"Indications and Usage for Depo-Provera Contraceptive Drugs.com last updated on Oct 1, 2020. https:\/\/www.drugs.com\/pro\/depo-provera-contraceptive.html."},{"key":"249_CR14","volume-title":"World Health Organization model list of essential medicines: 21st list 2019","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization; 2019. hdl:10665\/325771. WHO\/MVP\/EMP\/IAU\/2019.06. License: CC BY-NC-SA 3.0 IGO."},{"issue":"6","key":"249_CR15","doi-asserted-by":"publisher","first-page":"499 e1","DOI":"10.1016\/j.ajog.2013.02.013","volume":"208","author":"SR Ammerman","year":"2013","unstructured":"Ammerman SR, Nelson A. A new progestogen-only medical therapy for outpatient management of acute, abnormal uterine bleeding: a pilot study. Am J Obstet Gynecol. 2013;208(6):499 e1-5.","journal-title":"Am J Obstet Gynecol"},{"key":"249_CR16","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0010-7824(97)00174-1","volume":"56","author":"W Kuhnz","year":"1997","unstructured":"Kuhnz W, Heuner A, Humpel M, et al. In vivo conversion of norethisterone and norethisterone acetate to ethinyl estradiol in postmenopausal women. Contraception. 1997;56:379\u201385.","journal-title":"Contraception"},{"issue":"6","key":"249_CR17","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1210\/jc.2007-0044","volume":"92","author":"MC Chu","year":"2007","unstructured":"Chu MC, Zhang X, Gentzschein E, Stanczyk Z, Lobo RA. Formation of ethinyl estradiol in women during treatment with norethindrone acetate. J Clin Endocrinol Metab. 2007;92(6):2205\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"249_CR18","first-page":"3","volume":"38","author":"D Mansour","year":"2012","unstructured":"Mansour D. Safer prescribing of therapeutic norethisterone for women at risk of venous thromboembolism. BMJ Sex Reprod Health. 2012;38:3.","journal-title":"BMJ Sex Reprod Health"},{"issue":"7\u20138","key":"249_CR19","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1177\/106002809502907-817","volume":"29","author":"B Kaplan","year":"1995","unstructured":"Kaplan B. Desogestrel, norgestimate, and gestodene: the newer progestins. Ann Pharmacother. 1995;29(7\u20138):736\u201342.","journal-title":"Ann Pharmacother"},{"issue":"suppl 3","key":"249_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/14730782.2000.12288986","volume":"5","author":"W Oelkers","year":"2000","unstructured":"Oelkers W. Drospirenone \u2013 a new progestogen with antimineralocorticoid activity, resembling natural progesterone. Eur J Contracept Reprod Health Care. 2000;5(suppl 3):17\u201324.","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"249_CR21","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1196\/annals.1290.033","volume":"997","author":"HPG Schneider","year":"2003","unstructured":"Schneider HPG. Androgens and antiandrogens. Ann N Y Acad Sci. 2003;997:292\u2013306.","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"249_CR22","first-page":"26","volume":"1","author":"C Pallavi","year":"2015","unstructured":"Pallavi C, Dhamangaonkar KA, Saxena A. Levonorgestrel intrauterine system (Mirena): an emerging tool for conservative treatment of abnormal uterine bleeding. J Mid Life Health. 2015;1(6):26\u201330.","journal-title":"J Mid Life Health"},{"key":"249_CR23","doi-asserted-by":"crossref","unstructured":"Combined hormonal contraceptive for heavy menstrual bleeding. Cochrane Review. 2019.","DOI":"10.1002\/14651858.CD000154.pub3"},{"key":"249_CR24","doi-asserted-by":"publisher","unstructured":"Barrington, JW, Bowen-Simpkins P. The levonorgestrel intrauterine system in the management of menorrhagia BJOG. first published: 19 2005. https:\/\/doi.org\/10.1111\/j.1471-0528.1997.tb11542.x.","DOI":"10.1111\/j.1471-0528.1997.tb11542.x"},{"issue":"5","key":"249_CR25","first-page":"1104","volume":"113","author":"AM Kaunitz","year":"2009","unstructured":"Kaunitz AM, Meredith M, Meredith S, Inki P, Kubba A, Sanchez-Ramos L. Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy. Menstrual Bleeding. 2009;113(5):1104\u201316.","journal-title":"Menstrual Bleeding"},{"issue":"21","key":"249_CR26","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1001\/jama.2019.5248","volume":"321","author":"AM Kaunitz","year":"2019","unstructured":"Kaunitz AM. Abnormal uterine bleeding in reproductive-age women. JAMA. 2019;321(21):2126\u20137. https:\/\/doi.org\/10.1001\/jama.2019.5248.","journal-title":"JAMA"},{"key":"249_CR27","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S0010-7824(02)00283-4","volume":"65","author":"I Monteiro","year":"2002","unstructured":"Monteiro I, Bahamondes L, Diaz J, Perrotti M, Petta C. Therapeutic use of levonorgestrel-releasing intrauterine system in women with menorrhagia: a pilot study. Contraception. 2002;65:325\u20138.","journal-title":"Contraception"},{"issue":"2","key":"249_CR28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/ijgo.12293","volume":"139","author":"M Louie","year":"2017","unstructured":"Louie M, Spencer J, Wheeler S, Ellis V, Toubia T, Schiff L, Siedhoff MT, Moulder JK. Comparison of the levonorgestrel-releasing intrauterine system, hysterectomy, and endometrial ablation for heavy menstrual bleeding in a decision analysis model. Int J Gynecol Obstet. 2017;139(2):121\u20139.","journal-title":"Int J Gynecol Obstet"},{"issue":"2","key":"249_CR29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.contraception.2009.02.008","volume":"80","author":"D Hubacher","year":"2009","unstructured":"Hubacher D, Lopez I, Steiner MJ, et al. Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence based comparisons. Contraception. 2009;80(2):113\u20138.","journal-title":"Contraception"},{"key":"249_CR30","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/j.1471-0528.2012.03298.x","volume":"119","author":"S Wilailak","year":"2012","unstructured":"Wilailak S, Vipupinyo C, Suraseranivong V, et al. Depot medroxypogesteroneacetate and epithelial ovarian cancer: a multicentre case-control study. BJOG. 2012;119:772\u20137.","journal-title":"BJOG"},{"issue":"2","key":"249_CR31","first-page":"186","volume":"49","author":"S Wilailak","year":"1991","unstructured":"Wilailak S. The WHO collaborative study of neoplasia and steroid contraceptives. In J Cancer. 1991;49(2):186-90 13.","journal-title":"In J Cancer"}],"container-title":["Contraception and Reproductive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40834-023-00249-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40834-023-00249-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40834-023-00249-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T07:23:47Z","timestamp":1700465027000},"score":1,"resource":{"primary":{"URL":"https:\/\/contraceptionmedicine.biomedcentral.com\/articles\/10.1186\/s40834-023-00249-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,9]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["249"],"URL":"https:\/\/doi.org\/10.1186\/s40834-023-00249-5","relation":{},"ISSN":["2055-7426"],"issn-type":[{"value":"2055-7426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,9]]},"assertion":[{"value":"9 October 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares she has no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}